摘要
中国仓鼠卵巢细胞(CHO细胞)系是真核表达系统,其制备重组乙型肝炎(乙肝)疫苗的发展前景较之原核的酵母细胞系更好。该文综述了国产重组乙肝疫苗(CHO细胞)的临床效果,认为重组乙肝疫苗(CHO细胞)具有良好的安全性;无论是新生儿、儿童或是成人易感者接种3剂重组乙肝疫苗(CHO细胞)后,乙肝病毒表面抗体(抗-HBs)阳转率都可达到90%以上,抗体几何平均浓度(GMC)约为200毫国际单位/毫升(mIU/ml);以20μg/ml剂量为乙肝病毒表面抗原(HBsAg)和乙肝病毒e抗原(HBeAg)双阳性母亲的新生儿做母婴阻断,阻断率可达90%以上;将重组乙肝疫苗(CHO细胞)用于人群乙肝免疫预防,可将新一代人的HBsAg阳性率降到1%以下。这些研究结果提示,重组乙肝疫苗(CHO细胞)的效果与重组乙肝疫苗(酵母)相当,可用于中国的乙肝预防。
The mammalian Chinese hamster ovary （CHO） cell system is more perspective than yeast cell system in developing recombinant Hepatitis B vaccine. In this article the clinical effects of the Chinese made CHO recombinant Hepatitis B vaccine is reviewed. The research results showed that the vaccine was quite safe and for neonate, children and adult susceptibles, the anti-HBs positive rates can reach over 90 % while the GMCs were about 200 mIU/mL after a 3-dose schedule administration; and for children born to HBsAg and HBeAg positive mothers, the vaccine can prevent over 90% of them from being infected with HBV; In the practice of community prevention of Hepatitis B, the vaccine can reduce the HBsAg positive rates to under 1% in the new generation of people. So, it is concluded that the CHO recombinant Hepatitis B vaccine is as affective as yeast derived vaccine and can be used in the prevention of Hepatitis B in China.
出处
《中国计划免疫》
2006年第4期315-317,共3页
Chinese Journal of Vaccines and Immunization
